Recent Investment Analysts’ Ratings Updates for Illumina (ILMN)

Illumina (NASDAQ: ILMN) recently received a number of ratings updates from brokerages and research firms:

  • 1/11/2019 – Illumina was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $347.00 price target on the stock. According to Zacks, “In the past six months, Illumina has outperformed its industry. The company has received regulatory approval for its next-generation sequencing (NGS) system — MiSeqDx in China. Illumina also released the S4 200 cycle kit for the NovaSeq platform in the quarter. Additionally, improving margins buoy optimism. Further, the company’s raised 2018 EPS guidance indicates that the company will deliver solid results in the quarters to come. On the flip side, seasonality in DTC functionality continues to dent Illumina’s microarray sales. Funding issues restrict growth. The company, which is currently a bit overvalued, is operating in a tough competitive landscape.”
  • 1/7/2019 – Illumina had its price target lowered by analysts at Morgan Stanley from $320.00 to $288.00. They now have an “equal weight” rating on the stock.
  • 1/3/2019 – Illumina was upgraded by analysts at UBS Group AG from a “neutral” rating to a “buy” rating. They now have a $370.00 price target on the stock, up previously from $340.00.
  • 12/31/2018 – Illumina was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “In the past six months, Illumina has outperformed its industry. The company has received regulatory approval for its next-generation sequencing (NGS) system — MiSeqDx in China. Illumina also released the S4 200 cycle kit for the NovaSeq platform in the quarter. Additionally, improving margins buoy optimism. Further, the company’s raised 2018 EPS guidance indicates that the company will deliver solid results in the quarters to come. On the flip side, seasonality in DTC functionality continues to dent Illumina’s microarray sales. Funding issues restrict growth. The company, which is currently a bit overvalued, is operating in a tough competitive landscape.”

Illumina stock opened at $307.07 on Monday. Illumina, Inc. has a one year low of $207.51 and a one year high of $372.61. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46. The firm has a market cap of $44.87 billion, a price-to-earnings ratio of 76.77, a P/E/G ratio of 1.99 and a beta of 1.11.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.26 by $0.26. The firm had revenue of $853.00 million for the quarter, compared to the consensus estimate of $825.65 million. Illumina had a return on equity of 27.10% and a net margin of 21.09%. The company’s revenue was up 19.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.11 EPS. Equities research analysts expect that Illumina, Inc. will post 5.76 earnings per share for the current fiscal year.

In other Illumina news, SVP Mostafa Ronaghi sold 10,000 shares of the firm’s stock in a transaction on Monday, November 12th. The stock was sold at an average price of $314.63, for a total value of $3,146,300.00. Following the sale, the senior vice president now owns 79,612 shares of the company’s stock, valued at approximately $25,048,323.56. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction on Wednesday, October 24th. The shares were sold at an average price of $310.58, for a total value of $1,024,914.00. Following the completion of the sale, the director now directly owns 382,304 shares in the company, valued at approximately $118,735,976.32. The disclosure for this sale can be found here. In the last ninety days, insiders sold 56,404 shares of company stock worth $17,701,927. Company insiders own 0.54% of the company’s stock.

Several hedge funds have recently modified their holdings of ILMN. Financial Enhancement Group LLC acquired a new stake in shares of Illumina during the 3rd quarter valued at $400,000. Nan Shan Life Insurance Co. Ltd. acquired a new stake in shares of Illumina during the 3rd quarter valued at $52,099,000. Handelsbanken Fonder AB acquired a new stake in shares of Illumina during the 3rd quarter valued at $8,442,000. Pacer Advisors Inc. boosted its holdings in shares of Illumina by 18.2% during the 3rd quarter. Pacer Advisors Inc. now owns 13,597 shares of the life sciences company’s stock valued at $4,991,000 after acquiring an additional 2,092 shares in the last quarter. Finally, Jackson Square Partners LLC boosted its holdings in shares of Illumina by 7.7% during the 3rd quarter. Jackson Square Partners LLC now owns 1,429,221 shares of the life sciences company’s stock valued at $524,609,000 after acquiring an additional 102,639 shares in the last quarter. 88.88% of the stock is currently owned by hedge funds and other institutional investors.

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Featured Story: How are Outstanding Shares Different from Authorized Shares?

Receive News & Ratings for Illumina Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply